Sign In
Buy ARKG
$41.43
+1.32 (+3.29%)
At Close: Jun 26, 2026
Biotech ETFs Put Up Strong Show in 1H 2026: More Gains Ahead?
01:01pm, Tuesday, 23'rd Jun 2026
Biotech ETFs are surging in 2026 as a friendlier FDA, strong M&A activity and AI-driven drug discovery fuel optimism for more upside.
Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC
01:00am, Tuesday, 16'th Jun 2026
Biotech investors are far more selective than they were during the pandemic-era boom, JPMorgan's top EMEA healthcare investment bankers told CNBC. Many biotech companies are now pursuing a dual-trac
Cathie Wood, Bill Ackman Share 3 Stock Investments In Common: Can You Guess What They Are?
04:41pm, Thursday, 11'th Jun 2026
Two of the most well-known investors are betting on the same three Magnificent Seven stocks. Here's a look at the stocks owned by both Cathie Wood and Bill Ackman.
COVID, Ukraine, ChatGPT Expose Thematic Fund Gaps
11:46am, Friday, 13'th Mar 2026
FactSet analysis shows thematic funds respond differently to market shocks, with some genomic ETFs rising after COVID while others lagged.
ARKG: Cathie Wood's Biotech Product Is In Rally Mode
05:50pm, Wednesday, 28'th Jan 2026
ARK Genomic Revolution ETF (ARKG) maintains a "Buy" rating, driven by strong technicals and momentum despite a premium valuation. ARKG has outperformed XLV and SPY over the past year, returning 23% si
ARK Invest Boosts Gene-Editing Bets While Cutting Consumer Tech Exposure
12:23pm, Monday, 05'th Jan 2026
Cathie Wood's ARK Invest is entering 2026 with a noticeably sharper bet on early-stage biotechnology, while selectively reducing exposure to consumer technology
TSLA: Cathie Wood Dumps $30 Million Worth Tesla Stock
12:51pm, Monday, 29'th Dec 2025
Cathie Wood's Ark Invest increased stakes in gene-editing and autonomous mobility companies while trimming holdings in Tesla (TSLA) and Rocket Lab (RKLB).Sellin
My Top 5 Biotech Stocks Big Pharma Could Buy Next
01:29pm, Monday, 06'th Oct 2025
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of
ARKG: I'm Holding Off Buying For These 3 Reasons
08:25am, Thursday, 28'th Aug 2025
I maintain a hold rating on ARK Genomic Revolution ETF due to unprofitable top holdings, high operating costs, and limited approved treatments despite revenue growth. ARKG's high expense ratio and lac
Cathie Wood's Top 10 Stock Picks: Unpacking Ark Funds Innovation Picks For The Next Decade
01:02pm, Thursday, 14'th Aug 2025
Ark Invest CEO Cathie Wood is known for her stock picks over the last decade, handpicking many of the growth stocks that find their way into the company's ETFs.
ARKG: April's Wash-Out Low Is Encouraging, Healthcare Still Soft
09:43am, Friday, 25'th Jul 2025
I reiterate a soft buy rating on ARKG, despite recent sector weakness and mixed technicals, due to its rebound and improving valuation. ARKG stands out for its concentrated portfolio, high risk/reward
Cathie Wood Comeback: These 2 Ark ETFs are Sailing Higher Again
12:31pm, Monday, 09'th Jun 2025
It's probably time to give Cathie Wood the benefit of the doubt as the tides turn back in disruptive innovation's favor.
Best-Performing ETFs of Last Week
09:00am, Wednesday, 19'th Feb 2025
Wall Street was upbeat last week, despite the release of hot January inflation data.
2 Actively Managed ETFs That Got Smoked by the S&P 500 Last Year
12:12pm, Wednesday, 05'th Feb 2025
Low-cost passive index investing (in the S&P 500 or Nasdaq 100) has been key to impressive results in recent years.
Can Health Care ETFs Aid Your Portfolio?
07:49am, Monday, 03'rd Feb 2025
The Health Care Select Sector SPDR ETF (XLV) was up approximately 6% year-to-date as of January 29. While it is still early days, this performance is already twice as robust as the sector ETF's perfor
